There have been many inconsistencies in the naming, classifying, and diagnosing of malignant histiocytosis [1]. The original description of the disease was based on visual inspection and then on light microscopy. Later, as immunological and molecular techniques became available, many cases that were originally diagnosed as malignant histiocytosis were shown to be T cell or B cell lymphomas [2]. Therefore, the 2001 World Health Organization guidelines required the demonstration that there was no T or B cell specific gene rearrangements; however, in the 2008 guideline, this stipulation was abandoned [3] [4].

The classification and naming of malignant histiocytosis are also somewhat controversial. The disease has been referred to, among others, as atypical Hodgkin’s disease, histiocytic lymphoma, histiocytic medullary reticulosis [1], histiocytic sarcoma, [3] [5], or true histiocytic lymphoma.

The disease is very rare, and sometimes coexists with B or T cell neoplasms, or appears subsequently. It can present in various organs, mainly the lymph nodes, skin, gastrointestinal tract, and spleen, but many other sites can harbor malignant histiocytosis. Systemic symptoms, such as fever, fatigue, night sweats, and weight loss are often observed. Lymphadenopathy, splenomegaly, hepatomegaly, skin conditions such as rashes and multiple tumors, as well as gastrointestinal and other problems, are also encountered.

Anemia, thrombocytopenia, and leukopenia are frequent.

The tumor cells are large, oval-shaped or round, with eosinophilic cytoplasm that can look foamy because of elevated lipid levels. The cells do not adhere to each other. Bi- or multinucleated cells are not uncommon, and the nuclei can have multiple lobes. Mitoses and phagocytic activity are often observed. Lysosomes are seen in the cytoplasm in substantial numbers, but not Birbeck granules, which are cytoplasmic inclusions characteristic of Langerhans cells [6]. Various benign immune cells are also present - lymphocytes, neutrophils, eosinophils, and non-malignant histiocytes.

Immunological methods are used extensively for the diagnosis of malignant histiocytosis; a large number of histiocytic and other markers are available. Except for the extremely rare cases of transdifferentiation, an immunological examination should show the reaction with macrophage markers and lack of reaction with markers for myeloid cells, dendritic and Langerhans cells, B cells, T cells, and epithelial cells. Histiocytic markers are CD163 and CD 68, the latter being used regularly, although it is known to react with other types of cancer cells in addition to those of monocytic/macrophage origin [3]. CD163, which is a hemoglobin scavenger receptor, is essentially specific for macrophages or histiocytes [7]. Among other macrophage specific markers are CD11c, CD14, and CD31. No immunochemical staining with myeloid markers (myeloperoxidase, CD33 and CD34), dendritic cell markers (CD1a, CD21 and CD35), or T or B cell markers should be observed [6] [8] [9] [10], although, as mentioned above, a few examples of transdifferentiation have been described. Similarly, in most cases, immunoglobulin or T cell receptor gene rearrangements are not detected.

Benign and malignant histiocytes carry similar markers, therefore distinguishing them has to be based on cell morphology. Distinction from Langerhans cell neoplasms is by immunological markers, in addition to an absence of the characteristic Birbeck granules of Langerhans cells. Anaplastic large cell lymphoma, the cells of which are morphologically similar to malignant histiocytes, is most easily mistaken for malignant histiocytosis. However, anaplastic lymphoma cells express CD30, ALK-1, and other markers. Moreover, they harbor a characteristic chromosomal translocation, and T cell receptor gene rearrangements [3].

Treatment for malignant histiocytosis is challenging due to its aggressive nature. It often involves a combination of chemotherapy and immunotherapy to target the abnormal histiocytes. Corticosteroids may also be used to reduce inflammation and control symptoms. In some cases, bone marrow or stem cell transplantation may be considered, especially if the disease is resistant to initial treatments. The choice of treatment depends on the patient's overall health, the extent of the disease, and response to initial therapies.

The prognosis for malignant histiocytosis is generally poor due to its aggressive nature and tendency to affect multiple organs. However, early diagnosis and treatment can improve outcomes. The response to treatment varies, with some patients achieving remission while others may experience recurrent or progressive disease. Ongoing research is focused on developing more effective therapies to improve survival rates and quality of life for affected individuals.

The exact cause of malignant histiocytosis is not well understood. It is believed to result from genetic mutations that lead to the uncontrolled growth of histiocytes. Some cases have been linked to viral infections or immune system dysfunction, but these associations are not consistent across all patients. Research is ongoing to better understand the underlying mechanisms that contribute to the development of this disease.

Malignant histiocytosis is an extremely rare condition, with only a small number of cases reported worldwide. It can occur at any age but is more commonly diagnosed in adults. There is no clear gender or ethnic predilection, and due to its rarity, comprehensive epidemiological data is limited. The scarcity of cases makes it difficult to conduct large-scale studies, which hinders the development of standardized treatment protocols.

The pathophysiology of malignant histiocytosis involves the abnormal proliferation of histiocytes, which are derived from monocytes, a type of white blood cell. These cells accumulate in various tissues and organs, disrupting normal function. The exact mechanisms driving this proliferation are not fully understood but may involve genetic mutations and dysregulation of signaling pathways that control cell growth and survival. This leads to the aggressive nature of the disease and its widespread impact on the body.

Currently, there are no known preventive measures for malignant histiocytosis due to its unclear etiology and rarity. General recommendations for maintaining a healthy immune system, such as a balanced diet, regular exercise, and avoiding known risk factors for immune dysfunction, may be beneficial but are not specific to preventing this disease. Ongoing research may eventually identify specific risk factors or genetic markers that could lead to targeted prevention strategies.

Malignant histiocytosis is a rare and aggressive disorder characterized by the excessive proliferation of histiocytes, leading to multi-organ involvement and severe symptoms. Diagnosis requires a combination of clinical evaluation, laboratory tests, imaging, and biopsy. Treatment is challenging and often involves chemotherapy, immunotherapy, and possibly stem cell transplantation. The prognosis is generally poor, but early intervention can improve outcomes. The exact cause remains unclear, and there are no specific preventive measures currently available.

If you or someone you know is experiencing symptoms such as persistent fever, unexplained weight loss, fatigue, or enlarged organs, it is important to seek medical evaluation. Malignant histiocytosis is a rare condition, and its symptoms can mimic other diseases, making professional assessment crucial. Diagnosis involves various tests, and treatment requires specialized care. While the disease is serious, advancements in medical research continue to improve understanding and management options.

1. Low SE, Stafford JS. Malignant histiocytosis: a case report of a rare tumour presenting with spontaneous splenic rupture. J Clin Pathol. 2006;59(7):770-772
2. Wilson MS, Weiss LM, Gatter KC, Mason DY, Dorfman RF, Warnke RA. Malignant histiocytosis. A reassessment of cases previously reported in 1975 based on paraffin section immunophenotyping studies. Cancer. 1990;66(3):530-536.
3. Takahashi E, Nakamura S. Histiocytic sarcoma : an updated literature review based on the 2008 WHO classification. J Clin Exp Hematop. 2013;53(1):1-8.
4. Wetzler M, Kurzrock R, Goodacre AM, McLaughlin P, Ku S, Talpaz M. Transformation of chronic lymphocytic leukemia to lymphoma of true histiocytic type. Cancer. 1995;76(4):609-617.
5. Mathé G, Gerard-Marchant R, Texier JL, Schlumberger JR, Berumen L, Paintrand M. The two varieties of lymphoid tissue "reticulosarcomas", histiocytic and histioblastic types. Br J Cancer. 1970;24(4):687-695.
6. Pileri SA, Grogan TM, Harris NL, et al. Tumours of histiocytes and accessory dendritic cells: an immunohistochemical approach to classification from the International Lymphoma Study Group based on 61 cases. Histopathology. 2002;41(1):1-29.
7. Nguyen TT, Schwartz EJ, West RB, Warnke RA, Arber DA, Natkunam Y. Expression of CD163 (hemoglobin scavenger receptor) in normal tissues, lymphomas, carcinomas, and sarcomas is largely restricted to the monocyte/macrophage lineage. Am J Surg Pathol. 2005;29(5):617-624.
8. Sun W, Nordberg ML, Fowler MR. Histiocytic sarcoma involving the central nervous system: clinical, immunohistochemical, and molecular genetic studies of a case with review of the literature. Am J Surg Pathol. 2003;27(2):258-265.
9. Ralfkiaer E, Delsol G, O'Connor NT, et al. Malignant lymphomas of true histiocytic origin. A clinical, histological, immunophenotypic and genotypic study. J Pathol. 1990;160(1):9-17.
10. Hornick JL, Jaffe ES, Fletcher CD. Extranodal histiocytic sarcoma: clinicopathologic analysis of 14 cases of a rare epithelioid malignancy. Am J Surg Pathol. 2004;28(9):1133-1144.